PREDICTIVE PRESYMPTOMATIC TESTING MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-52508 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Predictive Presymptomatic Testing Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET
7.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PREDICTIVE PRESYMPTOMATIC TESTING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 23andMe Inc.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Abbott Laboratories
16.3 Bayer HealthCare AG
16.4 Biocartis SA
16.5 BioHelix Corporation
16.6 bioMerieux S.A.
16.7 Celera Corporation (Quest Diagnostics)
16.8 Cepheid (Danaher)
16.9 Daan Diagnostics Ltd.
16.10 EKF Diagnostics Holdings plc
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeMolecular Testing
Cytogenic Testing
Biochemical Testing
By Application
Breast and Ovarian Cancer
Colorectal Cancer
Alzheimer’s Disease
Multiple Endocrine Neoplasia Type 2
Haemochromatosis
Companies
23andMe Inc.
Abbott Laboratories
Bayer HealthCare AG
Biocartis SA
BioHelix Corporation
bioMerieux S.A.
Celera Corporation (Quest Diagnostics)
Cepheid (Danaher)
Daan Diagnostics Ltd.
EKF Diagnostics Holdings plc
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.